Best Practices for Evaluating Cognition in Parkinson’s Disease Clinical Trials
March 19, 2019 - Toronto ON CA

Xtalks

fbonilla@xtalks.com
Phone: 1 416.977.6555

The past two decades have seen multiple industry trials explore the impact of drug treatments (primarily dopaminergic therapies and cholinesterase inhibitors) on cognition in Parkinson’s disease (PD) and PD dementia (PDD).

More Information